The RheumNow Week in Review – 27 January 2017 Save

Dr. Cush reviews highlights from the past week on RheumNow.com.

1. CHMP sends a positive recommendation for tofacitinib to the EMA. This would be for the 5 mg bid dose mod-severe RA https://t.co/O2XfkDF6XB  (NOTE: video error says tocilizumab, when tofacitinib (Xeljanz) was intended!)

2. Janssen has applied to FDA for new indications (AS, PsA) for golimumab based on GO-ALIVE, GO-VIBRANT trials https://t.co/qTZMJtWmya

3. FDA has granted priority review designation for use of tocilizumab in giant cell artertitis based on GiACTA study https://t.co/qOeYvZnc9p

4. Canada to consider sticker warnings that "opioid painkillers can cause addiction and overdose" https://t.co/mzjDQIABng

5. Bronchiectasis Rheumatoid overlap syndrome (BROS): Study of 147 patients shows RA an independent risk factor for mortality in pts with bronchiectasis https://t.co/nCp4k0BGrw

6. Provacative ARD letter states Renal Bx should be done whenever treatment strategies depend on renal involvement https://t.co/2jO4ywKSSe

7. RAPID3 shows strong correlations w/ BASDAI (r=0.84) & ASDAS (r=0.74) in Axial SpA pts (similar to BASDAI) https://t.co/k1WgEBqI33

8. Among 103 SLE pts ~10% had "Rhupus" polyarthritis; they had less renal, but more joints, erosions, hi ESR/CRP levels https://t.co/TpNKquhSVH

9. Study of 565k people shows chronic PPI has a nearly 2 fold risk of C. dificile & 4 fold risk of campylobacter infxn https://t.co/3pik6fmEMc

10. Complement Driven Vasculopathy Underlies Neuropsychiatric Lupus 

11. C5a and Neutrophils as Early Mediators in Inflammatory Arthritis.

12. FDA Issues Draft Guidance on Biosimilar Interchangeability 

13. The Challenge of Screening for Obstructive Sleep Apnea